Autolus Therapeutics Soars as Needham Lifts Price Target on Strong Aucatzyl Sales
I'm PortAI, I can summarize articles.
Shares of Autolus Therapeutics surged 8.1% after Needham analyst Gil Blum raised the price target from $10 to $11, citing strong Aucatzyl sales of $76 million in its first year. Blum included Autolus in his conviction list, projecting the company could break even by 2028. He highlighted potential catalysts, including data from the FELIX study and obe-cel's applications in treating pediatric leukemia and lupus nephritis. Despite a positive outlook, investor skepticism about profitability and commercialization execution remains, indicating a complex narrative ahead.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Stock Invest The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments